To further explore this hypothesis, we have designed a randomized‐controlled trial comparing the angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, with the ARB, valsartan, to provide information on the effect of neprilysin inhibition on LV remodelling in patients at high risk after MI as a result of residual LVSD. Here, MME is linked to myocardial infarction.